دورية أكاديمية
أعرض في EDS

The Fim and FhaB adhesins play a crucial role in nasal cavity infection and Bordetella pertussis transmission in a novel mouse catarrhal infection model.

التفاصيل البيبلوغرافية
العنوان: The Fim and FhaB adhesins play a crucial role in nasal cavity infection and Bordetella pertussis transmission in a novel mouse catarrhal infection model.
المؤلفون: Holubova J; Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Stanek O; Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Juhasz A; Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic., Hamidou Soumana I; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, United States of America., Makovicky P; Institute of Molecular Genetics of the Czech Academy of Sciences, Czech Centre for Phenogenomics, Vestec, Czech Republic., Sebo P; Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.
المصدر: PLoS pathogens [PLoS Pathog] 2022 Apr 08; Vol. 18 (4), pp. e1010402. Date of Electronic Publication: 2022 Apr 08 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science, c2005-
مواضيع طبية MeSH: Adhesins, Bacterial*/metabolism , Bordetella pertussis*/genetics , Whooping Cough*/transmission, Adenylate Cyclase Toxin ; Animals ; Disease Models, Animal ; Humans ; Mice ; Mice, Inbred C57BL ; Myeloid Differentiation Factor 88 ; Nasal Cavity/microbiology ; Pertussis Vaccine ; Virulence Factors, Bordetella/genetics
مستخلص: Pulmonary infections caused by Bordetella pertussis used to be the prime cause of infant mortality in the pre-vaccine era and mouse models of pertussis pneumonia served in characterization of B. pertussis virulence mechanisms. However, the biologically most relevant catarrhal disease stage and B. pertussis transmission has not been adequately reproduced in adult mice due to limited proliferation of the human-adapted pathogen on murine nasopharyngeal mucosa. We used immunodeficient C57BL/6J MyD88 KO mice to achieve B. pertussis proliferation to human-like high counts of 108 viable bacteria per nasal cavity to elicit rhinosinusitis accompanied by robust shedding and transmission of B. pertussis bacteria to adult co-housed MyD88 KO mice. Experiments with a comprehensive set of B. pertussis mutants revealed that pertussis toxin, adenylate cyclase toxin-hemolysin, the T3SS effector BteA/BopC and several other known virulence factors were dispensable for nasal cavity infection and B. pertussis transmission in the immunocompromised MyD88 KO mice. In contrast, mutants lacking the filamentous hemagglutinin (FhaB) or fimbriae (Fim) adhesins infected the nasal cavity poorly, shed at low levels and failed to productively infect co-housed MyD88 KO or C57BL/6J mice. FhaB and fimbriae thus appear to play a critical role in B. pertussis transmission. The here-described novel murine model of B. pertussis-induced nasal catarrh opens the way to genetic dissection of host mechanisms involved in B. pertussis shedding and to validation of key bacterial transmission factors that ought to be targeted by future pertussis vaccines.
Competing Interests: The authors have declared that no competing interests exist.
References: mBio. 2015 Aug 18;6(4):. (PMID: 26286694)
Infect Immun. 2018 Mar 22;86(4):. (PMID: 29358336)
Infect Immun. 2017 Oct 18;85(11):. (PMID: 28784932)
Trends Microbiol. 2007 Oct;15(10):462-8. (PMID: 17920273)
Lancet Infect Dis. 2017 Sep;17(9):974-980. (PMID: 28623146)
Future Microbiol. 2010 Mar;5(3):455-69. (PMID: 20210554)
Nat Biotechnol. 1998 May;16(5):454-7. (PMID: 9592394)
Expert Rev Vaccines. 2014 Oct;13(10):1241-52. (PMID: 25182980)
Sci Rep. 2016 Sep 13;6:32774. (PMID: 27620673)
PLoS One. 2015 Nov 18;10(11):e0141823. (PMID: 26581078)
Infect Immun. 2008 Nov;76(11):5139-48. (PMID: 18765723)
J Gen Microbiol. 1970 Oct;63(2):211-20. (PMID: 4324651)
Clin Infect Dis. 2010 Sep 15;51(6):656-62. (PMID: 20704493)
Front Immunol. 2020 Sep 11;11:2181. (PMID: 33013916)
Respir Med. 2000 Aug;94(8):791-9. (PMID: 10955756)
Am J Physiol Lung Cell Mol Physiol. 2002 Apr;282(4):L833-9. (PMID: 11880310)
Infect Immun. 1999 May;67(5):2090-5. (PMID: 10225859)
Proc Biol Sci. 2016 Jan 13;283(1822):. (PMID: 26763701)
Cell Microbiol. 2016 Mar;18(3):384-98. (PMID: 26334669)
Front Cell Infect Microbiol. 2021 Jan 19;10:614994. (PMID: 33585281)
Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 2):S202-6. (PMID: 8876543)
Elife. 2021 Jun 07;10:. (PMID: 34097599)
Nat Rev Immunol. 2014 Aug;14(8):546-58. (PMID: 25060580)
Emerg Microbes Infect. 2019;8(1):169-185. (PMID: 30866771)
Infect Immun. 2004 Jun;72(6):3350-8. (PMID: 15155640)
Infect Immun. 2000 Jan;68(1):247-56. (PMID: 10603395)
J Infect Dis. 2014 Mar;209(6):913-21. (PMID: 24227794)
Mol Microbiol. 2007 Nov;66(4):1003-15. (PMID: 17927697)
Infect Immun. 2018 Oct 25;86(11):. (PMID: 30126900)
Antimicrob Agents Chemother. 2014 Aug;58(8):4931-4. (PMID: 24867963)
Infect Immun. 2017 May 23;85(6):. (PMID: 28396322)
Biologicals. 1994 Sep;22(3):233-42. (PMID: 7811457)
J Infect Dis. 2014 Apr 1;209 Suppl 1:S16-9. (PMID: 24626866)
mBio. 2015 May 26;6(3):e00500-15. (PMID: 26015497)
Proc Biol Sci. 2015 Dec 22;282(1821):20143085. (PMID: 26702035)
PLoS One. 2014 Jan 30;9(1):e85229. (PMID: 24497924)
PLoS One. 2014 Aug 01;9(8):e104064. (PMID: 25084094)
Infect Immun. 2013 Aug;81(8):2761-7. (PMID: 23690400)
Vaccines (Basel). 2015 Sep 14;3(3):751-70. (PMID: 26389958)
Mucosal Immunol. 2021 Sep;14(5):1183-1202. (PMID: 33976385)
Adv Drug Deliv Rev. 1998 Jan 5;29(1-2):3-12. (PMID: 10837577)
Am J Physiol Lung Cell Mol Physiol. 2019 Feb 1;316(2):L334-L347. (PMID: 30358438)
BMC Microbiol. 2012 Apr 23;12:61. (PMID: 22524455)
Infect Immun. 2013 May;81(5):1390-8. (PMID: 23429530)
PLoS Pathog. 2020 Aug 10;16(8):e1008512. (PMID: 32776984)
Clin Microbiol Infect. 2012 Sep;18(9):E340-6. (PMID: 22717007)
Clin Microbiol Rev. 2005 Apr;18(2):326-82. (PMID: 15831828)
Infect Immun. 1998 Apr;66(4):1718-25. (PMID: 9529102)
Infect Immun. 2012 Apr;80(4):1530-6. (PMID: 22252879)
PLoS One. 2013;8(3):e59263. (PMID: 23555643)
J Immunol. 2008 Oct 15;181(8):5587-97. (PMID: 18832717)
Infect Immun. 2006 May;74(5):2596-605. (PMID: 16622195)
Infect Immun. 2013 Jul;81(7):2371-8. (PMID: 23630952)
J Med Microbiol. 1994 Mar;40(3):205-13. (PMID: 8114072)
PLoS Pathog. 2017 Jul 24;13(7):e1006531. (PMID: 28742139)
Microbes Infect. 2006 Jul;8(8):2228-35. (PMID: 16787756)
J Immunol. 2003 Sep 15;171(6):3119-27. (PMID: 12960338)
Infect Immun. 2005 Jun;73(6):3636-45. (PMID: 15908393)
BMC Infect Dis. 2018 May 2;18(1):199. (PMID: 29716545)
Vaccine. 2006 Apr 12;24 Suppl 2:S2-54-5. (PMID: 16823926)
Science. 1982 Sep 3;217(4563):948-50. (PMID: 6287574)
mBio. 2019 Sep 24;10(5):. (PMID: 31551332)
AAPS J. 2015 May;17(3):493-505. (PMID: 25693488)
Infect Immun. 2012 Dec;80(12):4317-32. (PMID: 23027529)
Microb Pathog. 2003 Jul;35(1):19-29. (PMID: 12860455)
BMC Med. 2015 Jun 24;13:146. (PMID: 26103968)
Mucosal Immunol. 2018 Nov;11(6):1763-1776. (PMID: 30127384)
Infect Immun. 2014 Dec;82(12):5256-69. (PMID: 25287922)
J Med Microbiol. 1999 Jan;48(1):95-98. (PMID: 9920131)
J Immunol. 2017 Jul 1;199(1):263-270. (PMID: 28539433)
J Immunol. 2019 Dec 15;203(12):3293-3300. (PMID: 31732529)
FEBS J. 2011 Dec;278(23):4668-82. (PMID: 21740523)
Immunol Cell Biol. 2016 Apr;94(4):322-33. (PMID: 26437769)
Vaccines (Basel). 2020 Nov 19;8(4):. (PMID: 33228165)
J Infect. 2017 Jun;74 Suppl 1:S114-S119. (PMID: 28646950)
Infect Immun. 2018 Feb 20;86(3):. (PMID: 29203545)
Elife. 2015 Dec 09;4:e10766. (PMID: 26650353)
Infect Immun. 2010 Jul;78(7):2901-9. (PMID: 20421378)
Infect Immun. 2021 Nov 16;89(12):e0030421. (PMID: 34125597)
PLoS Pathog. 2021 Aug 4;17(8):e1009735. (PMID: 34347835)
Clin Infect Dis. 2010 Sep 15;51(6):663-7. (PMID: 20704492)
J Bacteriol. 2017 Oct 17;199(22):. (PMID: 28827216)
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):787-92. (PMID: 24277828)
Pathog Dis. 2016 Oct;74(7):. (PMID: 27609461)
J Exp Med. 2001 May 7;193(9):1035-44. (PMID: 11342588)
Mol Microbiol. 2010 Sep;77(6):1439-55. (PMID: 20633227)
Dis Model Mech. 2022 May 1;15(5):. (PMID: 35311902)
PLoS One. 2017 Jan 11;12(1):e0170027. (PMID: 28076445)
Toxins (Basel). 2017 Sep 24;9(10):. (PMID: 28946636)
Nat Rev Microbiol. 2014 Apr;12(4):274-88. (PMID: 24608338)
Nat Rev Immunol. 2017 Jun;17(6):376-390. (PMID: 28461704)
J Immunol. 2010 Aug 1;185(3):1711-9. (PMID: 20610650)
NPJ Vaccines. 2021 Jan 8;6(1):6. (PMID: 33420041)
J Immunol. 2017 Feb 1;198(3):1285-1296. (PMID: 28039302)
Microbes Infect. 2013 Sep-Oct;15(10-11):708-18. (PMID: 23811096)
Virology (Auckl). 2014;2014(5):1-9. (PMID: 25429207)
المشرفين على المادة: 0 (Adenylate Cyclase Toxin)
0 (Adhesins, Bacterial)
0 (Myeloid Differentiation Factor 88)
0 (Pertussis Vaccine)
0 (Virulence Factors, Bordetella)
تواريخ الأحداث: Date Created: 20220408 Date Completed: 20220422 Latest Revision: 20240826
رمز التحديث: 20240826
مُعرف محوري في PubMed: PMC9020735
DOI: 10.1371/journal.ppat.1010402
PMID: 35395059
قاعدة البيانات: MEDLINE
الوصف
تدمد:1553-7374
DOI:10.1371/journal.ppat.1010402